Content about Estrogen

April 1, 2014

Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

CINCINNATI — Prasco Labs on Tuesday announced that it has signed a marketing and distribution agreement with Eli Lilly and Co. to market the authorized generic version of Evista (raloxifene hydrochloride tablets), 60 mg strength, in the United States.

October 8, 2013

The Food and Drug Administration has approved a new treatment for hot flashes and the prevention of osteoporosis, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new treatment for hot flashes and the prevention of osteoporosis, the agency said.

The FDA announced the approval of Duavee (conjugated estrogens; bazedoxifene), made by Pfizer. The drug is for women who suffer from moderate to severe hot flashes associated with menopause, and is also designed to prevent osteoporosis after menopause.

July 2, 2013

i-Health unveiled its Estroven Weight Management, a supplement specifically formulated to address the physical changes of menopause plus deliver on a core benefit of helping peri/menopausal women manage their weight as they go through this stage of life.

CROMWELL, Conn. — i-Health on Monday unveiled its Estroven Weight Management, a supplement specifically formulated to address the physical changes of menopause plus deliver on a core benefit of helping peri/menopausal women manage their weight as they go through this stage of life.

May 3, 2013

Women who take low-dose oral contraceptives may be at increased risk of chronic pelvic-pain symptoms and pain during sexual climax, according to a new study.

SAN DIEGO — Women who take low-dose oral contraceptives may be at increased risk of chronic pelvic-pain symptoms and pain during sexual climax, according to a new study.

The study, scheduled for presentation to reporters at the American Urological Association's annual scientific meeting in San Diego on Tuesday, was conducted by researchers at New York University and the Waitemata District Health Board in Auckland, New Zealand, compared CPPS in young women who used oral contraceptives with the condition in those who didn't.

April 1, 2013

The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

JERUSALEM — The Food and Drug Administration has approved a new contraceptive therapy made by Teva Pharmaceutical Industries, Teva said Monday.

The drug maker announced the approval of Quartette (levonorgestrel, ethinyl estradiol and ethinyl estradiol) tablets. Teva said the drug represented the "next generation" of extended-regimen oral contraceptives and was designed to minimize breakthrough bleeding between scheduled periods.

January 30, 2013

A patch for treating menopause that the manufacturer calls the smallest is now available.

NEW YORK — A patch for treating menopause that the manufacturer calls the smallest is now available.

Noven Pharmaceuticals announced the availability of Minivelle (estradiol) transdermal system in pharmacies. The patch, which the Food and Drug Administration approved in October 2012, is designed for treating hot flashes and night sweats in women with menopause.

The patch has a surface area nearly the same as a dime at its lowest strength of 0.0375 mg-per-day and is 34% smaller than Noven's Vivelle-Dot patch, the company said.

November 14, 2012

The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

DREXEL HILL, Pa. — The Community Specialty Pharmacy Network has entered a contract with Dara BioSciences to distribute a nonsteroidal anti-estrogen product.

CSPN announced the agreement with Dara to distribute Soltamox (tamoxifen) solution for oral administration. The drug, a treatment for breast cancer, is for patients who have difficulty swallowing pills.

March 2, 2012

A generic drug maker has launched its version of an Abbott Labs drug.

JERUSALEM — A generic drug maker has launched its version of an Abbott Labs drug.

Teva Pharmaceutical Industries said it launched progesterone capsules in the 100-mg and 200-mg strengths, a generic version of Prometrium.

Prometrium is indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogen tablets. The drug also is indicated for use in secondary amenorrhea.

For the 12 months ended Jan. 31, Prometrium had sales of approximately $198 million, according to IMS Health data.

August 10, 2011

Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause, according to a report in the Aug. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

MIAMI — Soy isoflavone tablets do not appear to be associated with a reduction in bone loss or menopausal symptoms in women within the first five years of menopause, according to a report in the Aug. 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

June 1, 2011

The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration is investigating a possible link between a class of birth control pills and a higher risk of blood clots in the women taking them, the agency said.

October 21, 2010

The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug...

ARDEE, Ireland The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug maker said Friday.

 

The company said it plans to launch Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) early next year. The company said the contraceptive contains the lowest dosage of estrogen — 10 micrograms — of any oral contraceptive currently available in the U.S. market.

 

 

September 26, 2010

The Food and Drug Administration has approved a new oral contraceptive from Bayer HealthCare Pharmaceuticals....

SILVER SPRING, Md. The Food and Drug Administration has approved a new oral contraceptive from Bayer HealthCare Pharmaceuticals.

 

The FDA announced Friday the approval of Beyaz (estrogen and progestin) tablets. The pills also contain a folate known as levomefolate calcium. Low folate levels in the body are associated with such conditions as spina bifida, and physicians recommend that women of childbearing age supplement their diets with folate.

 

 

September 12, 2010

The Food and Drug Administration has approved a new dosage of an AstraZeneca drug for...

WILMINGTON, Del. The Food and Drug Administration has approved a new dosage of an AstraZeneca drug for treating breast cancer, AstraZeneca said Friday.

 

The Anglo-Swedish drug maker announced the approval of the 500-mg dose of the injected drug Faslodex (fulvestrant) for treating breast cancer that has spread to other parts of the body –– also known as metastasis –– in postmenopausal women after they have received anti-estrogen therapy. The new dosage replaces the previous 250-mg dose of the drug.

 

May 6, 2010

The Food and Drug Administration has approved a new oral contraceptive made by Bayer, the...